Implementation of blood glucose self-monitoring among insulin-dependent patients with type 2 diabetes in three rural districts in Rwanda: 6 months open randomised controlled trial.
Attitude of Health Personnel
Blood Glucose Self-Monitoring
/ adverse effects
Diabetes Mellitus, Type 2
/ blood
Feasibility Studies
Glycated Hemoglobin
/ metabolism
Health Knowledge, Attitudes, Practice
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Interviews as Topic
Patient Compliance
Randomized Controlled Trials as Topic
Research Design
Rural Population
Rwanda
diabetes & endocrinology
general diabetes
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
27 07 2020
27 07 2020
Historique:
entrez:
29
7
2020
pubmed:
29
7
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Most patients diagnosed with diabetes in sub-Saharan Africa (SSA) present with poorly controlled blood glucose, which is associated with increased risks of complications and greater financial burden on both the patients and health systems. Insulin-dependent patients with diabetes in SSA lack appropriate home-based monitoring technology to inform themselves and clinicians of the daily fluctuations in blood glucose. Without sufficient home-based data, insulin adjustments are not data driven and adopting individual behavioural change for glucose control in SSA does not have a systematic path towards improvement. This study explores the feasibility and impact of implementing self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes in rural Rwandan districts. This is an open randomised controlled trial comprising of two arms: (1) Intervention group-participants will receive a glucose metre, blood test strips, logbook, waste management box and training on how to conduct SMBG in additional to usual care and (2) Control group-participants will receive usual care, comprising of clinical consultations and routine monthly follow-up. We will conduct qualitative interviews at enrolment and at the end of the study to assess knowledge of diabetes. At the end of the study period, we will interview clinicians and participants to assess the perceived usefulness, facilitators and barriers of SMBG. The primary outcomes are change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness and adverse effects resulting from SMBG. Secondary outcomes include reliability and acceptability of SMBG and change in the quality of life of the participants. This study has been approved by the Rwanda National Ethics Committee (Kigali, Rwanda No.102/RNEC/2018). We will disseminate the findings of this study through presentations within our study settings, scientific conferences and publication in a peer-reviewed journal. PACTR201905538846394; pre-results.
Identifiants
pubmed: 32718924
pii: bmjopen-2019-036202
doi: 10.1136/bmjopen-2019-036202
pmc: PMC7389513
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
hemoglobin A1c protein, human
0
Banques de données
PACTR
['PACTR201905538846394']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e036202Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Environ Res Public Health. 2007 Jun;4(2):93-100
pubmed: 17617671
BMC Public Health. 2018 Sep 29;18(1):1148
pubmed: 30268115
J Diabetes Res. 2018 Feb 26;2018:6093595
pubmed: 29682580
Lancet Diabetes Endocrinol. 2015 Jun;3(6):402-403
pubmed: 26003752
BMJ Glob Health. 2019 Jun 17;4(3):e001449
pubmed: 31321086
J Diabetes Res. 2018 Jul 8;2018:3419290
pubmed: 30116738
JACC Heart Fail. 2013 Jun;1(3):230-6
pubmed: 24621875
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1176-1182
pubmed: 28766486
J Diabetes Res. 2017;2017:2657820
pubmed: 29362719
J Card Fail. 2018 Dec;24(12):849-853
pubmed: 30312764
Diabet Med. 2016 Jun;33(6):820-6
pubmed: 26482333
Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1):S90-4
pubmed: 26703219
Annu Rev Public Health. 2016;37:395-412
pubmed: 26735432
Diabetes Res Clin Pract. 2015 Apr;108(1):187-92
pubmed: 25697633
BMC Public Health. 2011 Jul 14;11:564
pubmed: 21756350
Diabet Med. 2008 Oct;25(10):1151-6
pubmed: 19046192
Diabetologia. 2009 Sep;52(9):1842-5
pubmed: 19565213
Diabetes Care. 2004 Jul;27(7):1761-73
pubmed: 15220264
Diabetes Care. 2013 Jul;36(7):2009-14
pubmed: 23378621
Diabetes Res Clin Pract. 2016 Feb;112:37-43
pubmed: 26655019
Diabetes Res Clin Pract. 2017 Apr;126:198-201
pubmed: 28259009
Lancet. 2010 Jun 26;375(9733):2254-66
pubmed: 20609971
BMJ. 2016 Apr 06;353:i1575
pubmed: 27052837